Skip to content

Tonic dystonia: clinical and genetic characterisation, longitudinal changes and risk factors

Tonic dystonia: clinical and genetic characterisation, longitudinal changes and risk factors - Tonic dystonia Cohort

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56936
Enrollment
425
Registered
2009-03-27
Start date
2009-03-27
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscle tone regulation disorder

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: patients with tonic dystonia

Exclusion criteria

Exclusion criteria: - mobile dystonia - patients with a known genetic form of dystonia, e.g. DYT1-DYT17, Wilson*s disease - lesions or diseases of the central nervous system (e.g. as a result of head trauma) - implantation of drug-delivery pump

Design outcomes

Primary

MeasureTime frame
Medical history is obtained following a semi-structured interview. The primary patient group will be evaluated with the CRPS diagnose form. 2 EDTA tubes of blood (20 ml) will be collected for genetic testing only during the first visit. Several self-administered questionnaires will be completed: 1). Hospital anxiety and depression scale (HADS); 2). Tampa scale for Kinesiophobia; 3). Pain coping inventory (PCI); 4). Numeric rating Scale Pain (NRS-Pain); 5). McGill Pain Questionnaire (MPQ); 6). Dissociative experience scale (DES); 7); Somatoform dissociation questionnaire (SDQ20); 8). SCOPA AUT; 9). Radboud Skills Questionnaire; 10). Questionnaire on walking & rising; 11). Questions about profession and education (first visit) The severity and progression of the dystonia, together with the impairments on daily activities, will be measured with the *DYstonia Assessment Scale (DYAS)* rating scale and the *Burke Fahn Marsden* (BFM) scale. A rapid finger movement task is performed to test the velocity and fluency of movements (bradykinesia). Quantative sensory testing is used to assess wind-up, pain thresholds and perception to touch, temperature and vibration. Diffuse Noxious Inhibitory Control (DNIC), a test that interrogates the function of endogenous pain regulation, will also be determined. Surface temperature of hands and feet are determined with an infrared skin temperature device. The ability to accurately recognise the laterality of pictures of left and right extremities is performed with the Recognise© lateralization computer program.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)